Brief: Sciclone Pharmaceuticals Says Nmpa Accepted Investigational New Drug Application Of Danyelza & Granulocyte- Macrophage Colony Stimulating Factor
20/04/2022 02:29
April 20 (Reuters) - SciClone Pharmaceuticals:
* NMPA ACCEPTED INVESTIGATIONAL NEW DRUG APPLICATION OF
DANYELZA &
GRANULOCYTE- MACROPHAGE COLONY STIMULATING FACTOR
Source text for Eikon: ID:nHKS2Nr7h3
Further company coverage: 6600.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on SciClone Pharmaceuticals (Holdings)
See all newsOneRobotics surges on plan to buy more shares
Brief: Onerobotics (Shenzhen) To Procure Affiliate Of Co To Acquire 59.9% Stake Of Nanoleaf Limited, Others
Brief: OneRobotics (Shenzhen) Says Final Offer Price Under Global Offering Is HK$73.80 Per H Share
Brief: Sciclone Pharmaceuticals (Holdings) Announces Proposal For Privatisation Of Co By Silver Pegasus Investment
Brief: SciClone Pharmaceuticals Says Trading In Shares Halted